Press Release Summary:
Manufactured under rigorous conditions toÂ ensure purity and low levels of cross-contamination, Next-Gen Sequencing Oligos are required for proper assembly of genome sample fragments. With cross-contamination thresholds as low as 0.25%Â or less, and both ISO 9001 and 13485 manufacturing available, sequencing adaptersÂ are suitable for life science research and molecular diagnostic applications.
Original Press Release:
Sigma® Life Science Releases Next-Gen Sequencing Oligos
Custom Next-Generation Sequencing Adapters Improve Target Sequence Assembly
ST. LOUIS, -- Sigma-Aldrich Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services business, released Next-Gen Sequencing Oligos, custom next-generation sequencing adapters that improve target sequence assembly. These oligos are expected to allow researchers to achieve better results from multiplexing experiments.
"Sigma-Aldrich is the first oligonucleotide manufacturer to provide a cross-contamination threshold," said Carlos Martinez, Development Manager at Sigma-Aldrich. "This gives our customers the confidence they need from the start, minimizing the time and expense created by the need to experiment with less consistent products to achieve proper sequence assembly."
Next-generation sequencing adapters are required for the proper assembly of genome sample fragments. Adapters, especially barcode sequences, containing unacceptably low full-length sequence or excessive cross-contamination with other barcode sequences can lead to compromised sequence read integrity and improper sequence assembly. These types of problems are often undetectable until the data analysis stage, which make them costly in terms of time and money.
Sigma's Next-Gen Sequencing Oligos are manufactured under rigorous conditions to ensure suitable purity and low levels of cross-contamination.
"With cross-contamination thresholds as low as 0.25% or less, and both ISO 9001 and 13485 manufacturing available, Next-Gen Sequencing Oligos are ideal for research, life science research tool and molecular diagnostic applications," said Martinez.
Next-Gen Sequencing Oligos enhance Sigma Life Science's portfolio of oligonucleotide products. For more information about Sigma Life Science's custom oligonucleotides, visit www.sigma.com/oligos.
About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.
About Sigma-Aldrich: Sigma-Aldrich, a leading Life Science and Technology company focused on enhancing human health and safety, manufactures and distributes 230,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units - Research, Applied and SAFC Commercial - Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 37 countries, has approximately 9,000 employees worldwide and had sales of $2.79 billion in 2014. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.
Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co. LLC., registered in the US and other countries.
CONTACT: Corporate Inquiries: Sigma-Aldrich, Karen Miller, Karen.Miller@sial.com